Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: 'It doesn’t work'
Nektar Therapeutics’ pegylation strategy on IL-2 promised to resolve one of the thorniest hurdles in cancer R&D, inspiring a record $1.85 billion deal by a group of cancer research specialists at Bristol-Myers Squibb who were intensely excited by NKTR-214 and the prospect of advancing a killer approach to checkpoint combos.
But an analyst who’s played a key role behind some of the most effective short attacks in biotech in recent years has just fired a torpedo at the mother ship, hoping to persuade investors that NKTR-214 — one of the most closely followed cancer drugs now in the clinic — is absolutely worthless.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.